Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...

Editor’s note: This post was updated on June 9 to include a statment from Pharmsource. People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on ...

DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...

Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...

Customers have known for months that the Dexcom G7 continuous glucose monitoring sensor had problems. Now, the company is ...

Editor's note: This article has been updated with a comment from a Pharmsource spokesperson. Continuous glucose monitoring specialist Dexcom has identified two lots of Dexcom G7 sensors (1725204004 ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...